Market Performance - The biopharmaceutical sector increased by 0.55% on January 6, with Liaoning Chengda leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Liaoning Chengda (600739) closed at 12.27, with a rise of 7.16% and a trading volume of 530,500 shares, amounting to a transaction value of 633 million yuan [1] - Dongbao Biological (300239) closed at 6.18, up by 5.64%, with a trading volume of 454,500 shares and a transaction value of 278 million yuan [1] - Olin Biological (616889) closed at 27.66, increasing by 3.83%, with a trading volume of 74,400 shares and a transaction value of 204 million yuan [1] - Kanghong Pharmaceutical (002773) closed at 33.75, up by 2.37%, with a trading volume of 249,700 shares and a transaction value of 838 million yuan [1] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 323 million yuan [2] - The net inflow from speculative funds was 104 million yuan [2] Detailed Capital Flow for Selected Stocks - Liaoning Chengda had a net inflow of 34.37 million yuan from institutional investors, while it faced a net outflow of 18.32 million yuan from retail investors [3] - Dongbao Biological saw a net inflow of 21.29 million yuan from institutional investors, with a net outflow of 13.16 million yuan from retail investors [3] - Tian Tan Biological (600161) had a net inflow of 18.06 million yuan from institutional investors, with a net outflow of 10.02 million yuan from retail investors [3]

Group 1 - The core objective of the investment work for 2026 has been established, emphasizing the need for extraordinary thinking, strength, and measures to address investment challenges and ensure economic growth [3] - The provincial government is focusing on optimizing the business environment and enhancing the confidence of private enterprises through various initiatives, including awards for outstanding companies and new policies to improve efficiency [4][5] - The Guangdong province is actively promoting new consumption policies and structural reforms to stimulate the consumer market, aiming for a vibrant economic recovery [6] Group 2 - The series of actions taken at the beginning of the year, from investment initiatives to enterprise services, are designed to create a synergistic effect that will support Guangdong's economic growth in the new year [7] - The emphasis on cultivating new productive forces and defining future lifestyles through innovative projects, such as the integration of AI in public services, reflects a strategic focus on long-term development [6]

Core Viewpoint - The article emphasizes the importance of Guangdong's "15th Five-Year Plan" as a critical period for economic development, with a focus on innovation and technology to achieve significant growth targets by 2035 [1][3]. Group 1: Economic Goals and Projections - Guangdong aims to double its economic output by 2035, reaching a total of 25 trillion yuan [1]. - Guangzhou's GDP is projected to reach 6 trillion yuan by 2035, effectively creating a "new Guangzhou" [3][5]. - The "15th Five-Year Plan" outlines specific growth targets, with Guangzhou being one of the few first-tier cities to announce concrete economic goals [3]. Group 2: Role of Guangzhou and Huangpu District - Guangzhou is positioned as a key player in driving economic growth, serving as a center for advanced manufacturing and technological innovation [3][10]. - Huangpu District contributes significantly to Guangzhou's economy, accounting for approximately 15% of the city's GDP and 40% of its industrial output [6][10]. - The district is home to major industries, including low-altitude economy and biomedicine, which are expected to be pivotal in the "15th Five-Year Plan" [10][20]. Group 3: Industry Innovations and Developments - The article highlights the emergence of low-altitude economy and biomedicine as major growth sectors, with Huangpu leading in these areas [10][20]. - Huangpu has established a comprehensive industrial chain in the low-altitude economy, housing over 50 related enterprises and achieving a total output value exceeding 10 billion yuan [17][18]. - In biomedicine, Huangpu is home to over 5,000 enterprises, including 528 high-tech firms, contributing significantly to the region's economic landscape [24][25]. Group 4: Strategic Importance of the Manufacturing Sector - The article underscores the shift towards a manufacturing-driven economy, with a focus on advanced manufacturing and strategic emerging industries [26][27]. - The "15th Five-Year Plan" prioritizes the establishment of a modern industrial system, emphasizing the need for technological integration within the manufacturing sector [26]. - Huangpu District is recognized as a critical area for fostering innovation and industrial growth, contributing to both local and national economic competitiveness [27][28].

Group 1: Economic Development and Innovation - The provincial secretary emphasizes the need for Guangzhou to implement the spirit of the 20th Central Committee and the Central Economic Work Conference, aiming for a strong start in the 14th Five-Year Plan [1][4] - The focus is on enhancing the low-altitude economy through advancements in unmanned aerial vehicle technology, with encouragement for companies to innovate and expand into diverse application scenarios [1] - The biopharmaceutical sector is highlighted as a key area for development, with a call for effective technology transfer and innovation mechanisms to improve product supply and market demand matching [2] Group 2: Public Safety and Governance - The provincial secretary inspects public transportation safety measures during the New Year holiday, emphasizing the importance of maintaining public order and safety in crowded areas [3] - There is a strong focus on collaborative efforts among various departments to ensure the safety and convenience of citizens and tourists during peak times [3] Group 3: Urban Development and Modernization - The need for Guangzhou to explore new paths for modern urban governance is stressed, with an emphasis on integrating historical preservation with urban quality improvement [4] - The city is encouraged to adopt a people-centered approach in urban planning and management, aiming for coordinated regional development and urban renewal [4]

本报讯 （记者王镜茹）12月30日晚，百奥泰生物制药股份有限公司（以下简称"百奥泰"）发布公告称，公司已于近日收到 合作伙伴Sandoz AG（以下简称"Sandoz"）支付的450万美元里程碑付款。此笔款项源于双方此前就BAT1706（贝伐珠单抗）注 射液签署的授权许可与商业化协议。 公告显示，该笔450万美元里程碑付款的到账，进一步充实了公司的现金储备，将为后续管线研发及国际化战略的推进提 供资金支持。 回溯此前合作，百奥泰于2021年9月8日与Sandoz达成协议，将BAT1706在美国、欧洲、加拿大及大部分其他未覆盖国际市 场的排他性产品商业化权益有偿许可给Sandoz。 根据当时签署的协议条款，该项合作的首付款及里程碑款总金额最高可达1.55亿美元，其中包括2750万美元的首付款、累 计不超过1.275亿美元的里程碑付款，以及两位数百分比的利润分成。 （编辑 张伟） ...

百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于 2021 年 9 月 8 日召开公司第一届董事会第二十七次会议，审议通过了《关于 BAT1706（贝 伐珠单抗）注射液签署授权许可与商业化协议的议案》，本次签署授权协议事项 不属于关联交易和重大资产重组事项，根据《上海证券交易所科创板股票上市规 则》及公司章程等相关规定，本议案无需提交股东大会审议。 自愿披露关于与 Sandoz AG 就 BAT1706（贝伐珠单 抗）注射液签署授权许可与商业化协议收到里程碑付 款的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司于北京时间 2021 年 9 月 8 日与 Sandoz AG（以下简称"Sandoz"）签署授 权许可与商业化协议，将公司的 BAT1706（贝伐珠单抗）注射液在美国、欧洲、 加拿大和大部分其它 BAT1706 合作未覆盖的国际市场的排他的产品商业化权益 有偿许可给 Sandoz（以下简称"协议"或"本协议"）。首付款及里程碑款总金额最 高至 1.55 亿美元，其中包括 2,750 万美 ...

公司于 2025 年 12 月 30 日收到立信出具的《关于变更百奥泰生物制药股份 有限公司 2025 年年报审计质量控制复核人的告知函》，具体情况如下： 证券代码：688177 证券简称：百奥泰 公告编号：2025-073 百奥泰生物制药股份有限公司 关于变更项目质量控制复核人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 百奥泰生制药股份有限公司（以下简称"公司"）于 2025 年 4 月 8 日和 2025 年 4 月 30 日分别召开了第二届董事会第二十四次会议和 2024 年年度股东大会， 审议通过了《关于续聘 2025 年度会计师事务所的议案》，同意续聘立信会计师事 务所（特殊普通合伙）（以下简称"立信"）为公司 2025 年度会计师事务所。 具体内容详见公司于 2025 年 4 月 9 日在上海证券交易所网站（www.sse.com.cn） 披露的《百奥泰生物制药股份有限公司关于续聘会计师事务所的公告》（公告编 号：2025-030）。 本次变更的项目质量控制复核人不存在违反《中国注册会计师职业道德 ...

百奥泰公告，公司于北京时间2021年9月8日与SandozAG签署授权许可与商业化协议，将公司的 BAT1706注射液在美国、欧洲、加拿大和大部分其它BAT1706合作未覆盖的国际市场的排他的产品商业 化权益有偿许可给Sandoz。首付款及里程碑款总金额最高至1.55亿美元，其中包括2,750万美元首付款、 累计不超过1.275亿美元里程碑付款和两位数百分比的利润分成。根据协议约定，公司于近日收到 Sandoz支付的450.00万美元里程碑付款。 来源：滚动播报 ...

Core Viewpoint - The announcement details the expected daily related transactions for the year 2026 by Baotai Biopharmaceutical Co., Ltd., emphasizing that these transactions are necessary for normal business operations and do not harm the interests of the company or minority shareholders [2][10]. Group 1: Daily Related Transactions Overview - The expected daily related transactions do not require shareholder meeting approval, as they fall within the board's authority [5]. - The board of directors approved the expected daily related transactions for 2026 during a meeting held on December 29, 2025, with non-related directors voting unanimously in favor [3]. - Independent directors also reviewed and approved the expected transactions, confirming that they align with the company's operational needs and adhere to principles of fairness and market pricing [4]. Group 2: Transaction Amounts and Categories - The expected transaction amounts for 2026 are presented in ten thousand yuan, with specific categories including leasing properties, purchasing technical services, and selling goods to related parties [6][8]. - The transactions are based on voluntary, equal, and mutually beneficial principles, with prices set according to market rates [9]. Group 3: Purpose and Impact of Transactions - The related transactions are essential for the company's normal production and operations, serving as a means to optimize resource use and reduce operational costs [10]. - The pricing policies for these transactions strictly follow principles of openness, fairness, and equivalence, ensuring no adverse effects on the company's ongoing operations, profitability, or asset independence [10].

证券代码：688177 证券简称：百奥泰 公告编号：2025-072 百奥泰生物制药股份有限公司 关于公司2026年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次日常关联交易预计事项无需提交股东会审议 百奥泰生物制药股份有限公司（以下简称"公司"或"百奥泰"）本次日常 关联交易是公司及子公司正常生产经营所必需，定价公允、结算时间与方式合理， 不存在损害公司及中小股东利益的情况，不会对关联方形成依赖，不影响公司的 独立性。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司于 2025 年 12 月 29 日召开第三届董事会第五次会议审议通过了《关于 公司 2026 年度日常关联交易预计的议案》，关联董事HUANG XIANMING（黄 贤明）回避表决，其余非关联董事一致审议通过该议案。审议程序符合《中华人 民共和国公司法》《中华人民共和国证券法》等法律法规以及《百奥泰生物制药 股份有限公司章程》的有关规定。 公司于 2025 年 12 月 29 日召开第三届董事 ...